Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women
Steven R. Cummings(University of California, San Francisco), C. Christiansen, David A. Cox(Bon Secours Heart & Vascular Institute), Michael R. McClung(Bone Health and Osteoporosis Foundation), Jean‐Yves Reginster(King Saud University), José Zanchetta(Universidad del Salvador), Messan G. Amewou-Atisso, Bruce Mitlak(Radius Health (United States)), Paul D. Miller(Colorado Center for Bone Research), Trevor J. Powles(Royal Marsden NHS Foundation Trust), John L. Stock(Eli Lilly (United States))
Cited by 113
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2012|2.9k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2018|1.8k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k